Search results
Novo Nordisk A/S (NYSE:NVO) Shares Sold by Mather Group LLC.
ETF DAILY NEWS· 6 days agoMather Group LLC. cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 57.9% during the fourth quarter, HoldingsChannel ...
Novo Nordisk: Q1 Earnings Snapshot
Houston Chronicle· 6 days agoBAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on...
Novo Asks for More Time to Answer Sanders on Ozempic’s Price
Bloomberg· 17 hours agoNovo Nordisk A/S is asking for more time to answer questions from US Senator Bernie Sanders on the...
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly...
Benzinga· 6 days agoNovo Nordisk A/S NVO is witnessing a surge in the number of patients starting on its weight-loss...
Novo boosts Wegovy shipments as Lilly rivalry pressures prices
Detroit News· 6 days agoNovo Nordisk A/S is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in...
‘Ozempic babies’: What the science says on whether GLP-1s lead to surprise pregnancies, and their...
CNN.com· 1 hour agoNumerous women have shared stories of “Ozempic babies” on social media. But the joy some experience...
Q1 2024 Novo Nordisk A/S Earnings Call (London-Based Investors)
Guru Focus· 5 days agoIt's been a very busy week for earnings and in other events, but we are ending the week on a high with the Q1 ratio of Novo Nordisk. The speakers don't really need introduction, but just out ...
Fresenius Medical beats earnings expectations, keeps outlook; shares sink
Reuters· 6 hours agoFresenius Medical Care beat first-quarter operating earnings expectations on Tuesday amid higher...
Why Weight-Loss Drugs Wegovy, Zepbound Are in Short Supply
The Business of Fashion· 6 days agoShortages have left patients already on the medications searching for their next dose and stymied...
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 6 days agoQuestions and Answers Call Participants Prepared Remarks: Operator Good day and thank you for standing by. Welcome to the Q1 2024 Novo Nordisk ...